Abstract: Objective To observe the efficacy of enticavir on long-term survival in patients with serum HBV DNA negative hepatitis B-induced primary liver cancer（PLC） after transcatheter arterial chemoembolization （TACE）. Methods 82 patients with advanced HBV-related PLC were recruited and divided into observation group and control group,with 41 cases in each group. The patients in control group was treated with TACE,and the patients in observation group was treated with entecavir for antiviral therapy after TACE. The Objective remission rate,disease control rate,serum liver function index after 48 weeks and 96 weeks,the progression-free survival （PFS） and overall survival （OS） at 2 years and 3 years,and serum HBV DNA positive rate during follow-up were compared between the two groups. Results The objective remission rates in observation group and in control group were 53.6% and 50.3%,respectively,and the disease control rates were 82.9% and 85.5%,respectively（P>0.05）;there were no significant differences as respect to serum levels of liver function index and serum fetoprotein between the two groups before and after the treatment （P>0.05）;the DFS rate and OS rate at 3-year were 61.0% and 73.2% in the observation group, much higher than those in the control group （36.6% and 51.2% respectively,P<0.05）;the positive rate of serum HBV DNA in the observation group was 2.4%,much lower than that in the control group（19.5%,P<0.05）. Conclusion The application of entecavir for antiviral treatment can improve the survival rate and avoid HBV DNA back to positivity,so that benefits the PLC patients with serum HBV DNA negative after TACE.

Key words: Hepatoma, HBV DNA, Transcatheter arterial chemoembolization, Enticavir, Long-term survival